MedCity News September 17, 2024
Nura Bio aims to treat neurodegeneration with a small molecule designed to block SARM1, a novel target involved in axon degeneration. Following positive Phase 1 results in healthy volunteers, the startup is now preparing for mid-stage clinical testing.
Neurodegenerative disorders progress in a variety of ways, but one characteristic many of them share is the breakdown of axons, a cable-like fiber that extends from a neuron and transmits electrical signals. While scientists have long known about axon degeneration, they haven’t had tools to stop it. Nura Bio’s lead drug candidate blocks a novel target associated with this damage to axons and the startup now has $68 million to proceed to a Phase 2 test.
The new financing announced Tuesday was...
Today's Sponsors
Today's Sponsor